Kazuhiko Tsutsumi

The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis.

Kazuhiko Tsutsumi, Y Inoue, Atsushi Shima et al. · Journal of Clinical Investigation · 1993 · 147 citations · Full text

Coronary Artery Lesions, Hyperlipidemia, Oxidative Stress +18

Synthesis and Hypolipidemic Activities of Novel 2-[4-[(Diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3<i>H</i>)-Quinazolinones

Yasuhisa Kurogi, Yasuhide Inoue, Kazuhiko Tsutsumi et al. · Journal of Medicinal Chemistry · 1996 · 117 citations

Lipid Preparation, Pharmaceutical Science, Biochemistry +9

The Relationship between Plasma High Density Lipoprotein Cholesterol Levels and Cholesteryl Ester Transfer Protein Activity in Six Species of Healthy Experimental Animals.

Kazuhiko Tsutsumi, Akifumi Hagi, Yasuhide Inoue · Biological and Pharmaceutical Bulletin · 2001 · 100 citations · Full text

Six Species, Plasma Hdl-c, Education +19

The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet

Masataka Kusunoki, T. Hara, Kazuhiko Tsutsumi et al. · Diabetologia · 2000 · 78 citations · Full text

Insulin Resistance, Metabolic Syndrome, Obesity +13

Relationship between serum concentrations of saturated fatty acids and unsaturated fatty acids and the homeostasis model insulin resistance index in Japanese patients with type 2 diabetes mellitus

Masataka Kusunoki, Kazuhiko Tsutsumi, Meiho Nakayama et al. · The Journal of Medical Investigation · 2007 · 75 citations · Full text